8-K: CEL-SCI Presents Promising Head and Neck Cancer Data at International Congress

CEL-SCI's Multikine shows a significant increase in overall survival for head and neck cancer patients with low PD-L1 expression, cutting the risk of death in half compared to standard care.

Summary

• CEL-SCI Corporation announced that its Chief Scientific Officer presented data on Multikine at the IDDST Annual Congress in Budapest.
• The presentation focused on a Phase 3 trial of Multikine in head and neck cancer patients with low PD-L1 expression.
• The study showed a 73% survival rate at 5 years for patients treated with Multikine plus standard of care, compared to 45% for standard of care alone.
• This represents a statistically significant improvement with a log rank p-value of 0.0015.
• The risk of death was reduced by half, from 55% to 27%, with a hazard ratio of 0.35.
• CEL-SCI is working to commence an FDA confirmatory Registration Study for Multikine based on these results.
• The target patient population for the confirmatory study will be newly diagnosed, treatment-naive patients with locally advanced primary squamous cell carcinoma of the head and neck, no lymph node involvement, and low PD-L1 tumor expression.
• Approximately 100,000 patients globally meet these criteria annually.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a significant improvement in survival rates and a reduced risk of death. The company is moving forward with a confirmatory study, which is also a positive sign. However, there are still risks associated with regulatory approvals and future trials.

Positives

• Multikine demonstrated a substantial improvement in survival rates for head and neck cancer patients with low PD-L1 expression.
• The 5-year survival rate of 73% with Multikine is significantly higher than the 45% survival rate with standard of care alone.
• The hazard ratio of 0.35 indicates a significant reduction in the risk of death.
• The FDA has given the go-ahead to conduct a smaller, focused, confirmatory Registration Study of 212 patients.
• Multikine has extensive safety and efficacy data from 750 patients.

Risks

• The company faces risks related to the inability to duplicate the clinical results in future studies.
• There are risks associated with the timely development of safe and effective products.
• The company may face difficulties in manufacturing its potential products.
• There is a risk of not receiving necessary regulatory approvals.
• The company may face challenges in raising the necessary capital.

Future Outlook

CEL-SCI is planning to commence an FDA confirmatory Registration Study for Multikine, focusing on a specific patient population with low PD-L1 expression. The company believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival.

Management Comments

• Dr. Talor stated that the survival benefit of Multikine observed from previous data is much higher than that which will be required to be successful in the confirmatory study.

Industry Context

The announcement highlights a potential alternative to checkpoint inhibitors for head and neck cancer patients with low PD-L1 expression, a group that does not typically respond well to those treatments. This could position Multikine as a significant player in the immunotherapy landscape for this specific patient population.

Comparison to Industry Standards

• The results of the Multikine trial are compared to checkpoint inhibitors like Keytruda and Opdivo, which are known to be more effective in patients with higher levels of PD-L1 expression.
• The 73% survival rate at 5 years for Multikine in the target population is significantly higher than the 45% survival rate observed in the control group, suggesting a potential advantage over standard of care alone.
• The hazard ratio of 0.35 indicates a substantial reduction in the risk of death compared to standard of care, which is a strong indicator of efficacy.

Stakeholder Impact

• Shareholders may view the positive clinical trial results favorably.
• Patients with head and neck cancer, particularly those with low PD-L1 expression, may benefit from this potential treatment.
• The company's employees may be impacted by the progress of the clinical trials and the potential for commercialization.

Next Steps

• CEL-SCI will commence an FDA confirmatory Registration Study for Multikine.
• The confirmatory study will enroll 212 patients with specific criteria: newly diagnosed, treatment-naive, locally advanced primary SCC of the head and neck, no lymph node involvement, and low PD-L1 tumor expression.

Key Dates

Keywords

Multikine, Head and Neck Cancer, Immunotherapy, PD-L1, Survival Rate, Clinical Trial, FDA, Oncology, Cancer Treatment, Phase 3 Trial